Risk factors for developing mineral bone disease in phenylketonuric patients

Molecular Genetics and Metabolism

Volumn 108, Issue 3, 2013, Pages 149-154

  Mirás, Alicia ^a   Bóveda, M Dolores ^a   Leis, María R ^a   Mera, Antonio ^a   Aldámiz Echevarría, Luís ^b   Fernández Lorenzo, José R ^c   Fraga, José M ^a   Couce, María L ^a  

^a Instituto de Salud Carlos III   (Spain)

^b HOSPITAL DE CRUCES   (Spain)

^c HOSPITAL XERAL CÍES   (Spain)

Author keywords

Bone mineralization; Densitometry; Nutrition; Osteopenia; Phenylketonuria; Tetrahydrobiopterin

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; CREATININE; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; PARATHYROID HORMONE; PHENYLALANINE; PHOSPHORUS; TETRAHYDROBIOPTERIN; VITAMIN D;

ADOLESCENT; ADULT; ARTICLE; BLOOD SAMPLING; BODY MASS; BONE DENSITOMETRY; BONE MASS; CALCIUM INTAKE; CHILD; CLINICAL ARTICLE; CROSS-SECTIONAL STUDY; FAT INTAKE; FATTY ACID BLOOD LEVEL; FEMALE; GENOTYPE; HUMAN; MALE; METABOLIC BONE DISEASE; NUTRITIONAL ASSESSMENT; OBSERVATIONAL STUDY; OSTEOPENIA; OSTEOPOROSIS; PHENOTYPE; PHENYLKETONURIA; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROTEIN INTAKE; QUESTIONNAIRE; RISK FACTOR; SCHOOL CHILD;

ADOLESCENT; ADULT; BIOPTERIN; BODY MASS INDEX; BONE AND BONES; BONE DEMINERALIZATION, PATHOLOGIC; BONE DENSITY; BONE DISEASES, METABOLIC; CALCIUM; CHILD; CROSS-SECTIONAL STUDIES; DIETARY PROTEINS; EICOSAPENTAENOIC ACID; FEMALE; HUMANS; MALE; MINERALS; MOTOR ACTIVITY; MUTATION; OSTEOPOROSIS; PHENYLALANINE HYDROXYLASE; PHENYLKETONURIAS; QUESTIONNAIRES; RISK FACTORS;

EID: 84874018848     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2012.12.008     Document Type: Article

References (34)

1. Trefz F.K., Burton B.K., Longo N., Casanova M.M., Gruskin D.J., Dorenbaum A., Kakkis E.D., Crombez E.A., Grange D.K., Harmatz P., Lipson M.H., Milanowski A., Randolph L.M., Vockley J., Whitley C.B., Wolff J.A., Bebchuk J., Christ-Schmidt H., Hennermann J.B. Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study. J. Pediatr. 2009, 154:700-707.
2. Dokoupil K., Gokmen-Ozel H., Lammardo A.M., Motzfeldt K., Robert M., Rocha J.C., van Rijn M., Ahring K., Bélanger-Quintana A., MacDonald A. Optimising growth in phenylketonuria: current state of the clinical evidence base. Clin. Nutr. 2012, 31:16-21.
3. Lambruschini N., Pérez-Dueñas B., Vilaseca M.A., Mas A., Artuch R., Gassió R., Gómez L., Gutiérrez A., Campistol J. Clinical and nutritional evaluation of phenylketonuric patients on tetrahydrobiopterin monotherapy. Mol. Genet. Metab. 2005, 86(Suppl.):S54-S60.
4. Bóveda M.D., Couce M.L., Castiñeiras D.E., Cocho J.A., Perez B., Ugarte M., Fraga J.M. The tetrahydrobiopterin loading test in 36 patients with hyperphenylalaninaemia: evaluation of response and subsequent treatment. J. Inherit. Metab. Dis. 2007, 30:812.
5. Pérez Dueñas B., Cambra F.J., Vilaseca M.A., Lambruschini N., Campistol J., Camacho J.A. New approach to osteopenia in phenylketonuric patients. Acta Paediatr. 2002, 91:899-904.
6. Barat P., Barthe N., Redonnet-Vernhet I., Parrot F. The impact of the control of serum phenylalanine levels on osteopenia in patients with phenylketonuria. Eur. J. Pediatr. 2002, 161:687-688.
7. Schwahn B., Mokov E., Scheidhauer K., Lettgen B., Schönau E. Decreased trabecular bone mineral density in patients with phenylketonuria measured by peripheral quantitative computed tomography. Acta Paediatr. 1998, 87:61-63.
8. Yannicelli S., Medeiros D.M. Elevated plasma phenylalanine concentrations may adversely affect bone status of phenylketonuric mice. J. Inherit. Metab. Dis. 2002, 25:347-361.
9. NIH Consensus Development Panel on osteoporosis prevention, diagnosis and therapy. Osteoporosis prevention, diagnosis and therapy. JAMA 2001, 285:785-795.
10. Zmuda J.M., Sheu Y.T., Moffett S.P. Genetic epidemiology of osteoporosis: past, present and future. Curr. Osteoporos. Rep. 2005, 3:111-115.
11. Bull F.C., Maslin T.S., Armstrong T. Global physical activity questionnaire (GPAQ): nine country reliability and validity study. J. Phys. Act. Health 2009, 6:790-804.
12. Liu Y.Z., Liu Y.J., Recker R.R., Deng H.W. Molecular studies of identification of genes for osteoporosis: the 2002 update. J. Endocrinol. 2003, 177:147-196.
13. Folch J., Lees M., Stanley G.H. A simple method for the isolation and purification of total lipids from animal tissues. J. Biol. Chem. 1957, 26:497-509.
14. Lepage G., Roy C.C. Direct transesterification of all classes of lipids in a one-step reaction. J. Lipid Res. 1986, 27:114-120.
15. Roato I., Porta F., Mussa A., DD́Amico L., Fiore L., Garelli D., Spada M., Ferracini R. Bone impairment in phenylketonuria is characterized by circulating osteoclast precursors and activated T cell increase. PLoS One 2010, 5:e14167.
16. Zancheta J.R., Plotkin H., Alvarez Filgueira M.L. Bone mass in children: normative values for the 2-20-year-old population. Bone 1995, 16:393S-399S.
17. WHO/FAO/UNU Expert Consultation Protein and amino acid requirements in human nutrition. Joint World Health Organ Tech Rep Ser. World Health Organ. Tech. Rep. Ser. 2007, 935:1-265.
18. Modan-Moses D., Vered I., Schwartz G., Anikster Y., Abraham S., Segev R., Efrati O. Peak bone mass in patients with phenylketonuria. J. Inherit. Metab. Dis. 2007, 30:202-208.
19. Koura H.M., Abdallah Ismail N., Kamel A.F., Ahmed A.M., Saad Hussein A., Effat L.K. A long-term study of bone mineral density in patients with phenilketonuria under diet therapy. Arch. Med. Sci. 2011, 7:493-500.
20. de Groot M.J., Hoesksma M., van Rijn M., Slart R.H., van Spronsen F.J. Relationship between lumbar bone mineral density and biochemical parameters in phenylketonuria patients. Mol. Genet. Metab. 2012, 105:566-570.
21. Mendes A.B., Martins F.F., Cruz W.M., da Silva L.E., Abadesso C.B., Boaventura G.T. Bone development in children and adolescents with PKU. J. Inherit. Metab. Dis. 2012, 35:425-430.
22. Barzel U.S. The skeleton as an ion exchange system: implications for the role of acid-base imbalance in the genesis of osteoporosis. J. Bone Miner. Res. 1995, 10:1431-1436.
23. Barzel U.S., Massey L.K. Excess dietary protein can adversely affect bone. J. Nutr. 1998, 128:1051-1053.
24. Bonjour J.P. Dietary protein: an essential nutrient for bone health. J. Am. Coll. Nutr. 2005, 24:526S-536S.
25. Fenton T.R., Tough S.C., Lyon A.W., Eliasziw M., Hanley D.A. Causal assessment of dietary acid load and bone disease: a systematic review & meta-analysis applying HillD́s epidemiologic criteria for causality. Nutr. J. 2011, 30:10-41.
26. Delmi M., Rapin C.-H., Bengoa J.-M., Delmas P.D., Vasey, Bonjour J.-P. Dietary supplementation in elderly patients with fractured neck of the femur. Lancet 1990, 335:1013-1016.
27. Teegarden D., Lyle R.M., McGabe G.P., McGabe L.D., Proulx W.R., Michon K., Knight A.P., Johnston C.C., Weaver C.M. Dietary calcium, protein and phosphorus are related to bone mineral density and content in young women. Am. J. Clin. Nutr. 1998, 68:749-758.
28. Hannam M.T., Tucker K.L., Dawson-Hughes B., Cupples L.A., Felson D.T., Kiel D.P. Effect of dietary protein on bone loss in elderly men and women: the Framingham Osteoporosis Study. J. Bone Miner. Res. 2000, 15:2504-2512.
29. Lage S., Bueno M., Andrade F., Prieto J.A., Delgado C., Legarda M., Sanjurjo P., Aldámiz-Echevarría L.J. Fatty acid profile in patients with phenylketonuria and its relationship with bone mineral density. J. Inherit. Metab. Dis. 2010, 10.1007/s10545-010-9189-0.
30. Nagasaka H., Tsukahara H., Takatani T., Sanayama Y., Takayanagi M., Ohura T., Sakamoto O., Ito T., Wada M., Yoshino M., Ohtake A., Yorifuji T., Hirayama S., Milda T., Fujimoto H., Mochizuki H., Hattori T., Okano Y. Cross-sectional study of bone metabolism with nutrition in adult classical phenylketonuric patients diagnosed by neonatal screening. J. Bone Miner. Metab. 2011, 29:737-743.
31. Kanis J.A., Oden A., Johnell O., Johansson H., De Laet C., Brown J., Burckhardt P., Cooper C., Christiansen C., Cummings S., Eisman J.A., Fujiwara S., Glüer C., Goltzman D., Hans D., Krieg M.A., La Croix A., McCloskey E., Mellstrom D., Melton L.J., Pols H., Reeve J., Sanders K., Schott A.M., Silman A., Torgerson D., van Staa T., Watts N.B., Yoshimura N. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos. Int. 2007, 18:1033-1046.
32. Sievanem H., Kannus P. Physical activity reduces the risk of fragility fracture. PLoS Med. 2007, 4:e222.
33. Schwahn B., Mokov E., Scheidhauer K., Lettgen B., Schönau E. Decreased trabecular bone mineral density in patients with phenylketonuria measured by peripheral quantitative computed tomography. Acta Paediatr. 1998, 87:61-63.
34. Yannicelli S., Medeiros D.M. Elevated plasma phenylalanine concentrations may adversely affect bone status of phenylketonuric mice. J. Inherit. Metab. Dis. 2002, 25:347-361.